A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 22, 2026

Conditions

Renal Cell CarcinomaFirst-line Treatment

Interventions

DRUG

AK104

anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)

DRUG

axitinib

an oral, small molecule, TKI selective for VEGFRs 1, 2 and 3; 5mg bid orally

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai